Business Wire

CA-AVIATRIX

9.3.2021 15:02:11 CET | Business Wire | Press release

Share
2021 Total Economic Impact™ Study of the Aviatrix Cloud Network Platform Shows 222% ROI

Aviatrix , the cloud network platform, today announced the availability of the 2021 Forrester's Total Economic Impact™ (TEI) Study commissioned by Aviatrix, conducted independently by Forrester Consulting in January 2021. The TEI Study is based on Forrester's in-depth interviews with Aviatrix customers and provides a quantitative, business value justification designed to help IT leaders. It demonstrates a composite cost-savings and business benefits analysis interviewed customers realized by leveraging the Aviatrix cloud network platform and provides a model for determining economic value in any organization.

The complete results of the TEI Study of Aviatrix can be found and downloaded here , where readers will learn how Aviatrix customers leverage more advanced cloud networking, security, and operational visibility for their cloud and multi-cloud network environments, helping them generate new revenue and ensure operational efficiency at significantly lower costs.

Key highlights of the TEI Study on Aviatrix cloud network platform Include:

  • Aviatrix pays for itself more than 2x in the span of three years (222% ROI)
  • Over $3 million in revenue and margin gains from new and existing customers attributed to multi-cloud readiness and faster time-to-market
  • Over $1 million in cost savings from operational efficiency and resource re-allocation
  • Over $4 million in business benefits and cost savings over three years

Cloud infrastructure is becoming the norm for many organizations. Decision makers may plan to focus on a single cloud platform, but they often need to support many due to acquisitions, client requirements, or app developer preferences. Each cloud service provider comes with its own processes, native constructs and tools that can slow cloud network operations. The Aviatrix cloud network platform helps organizations automate and control cloud network infrastructure, maintain security compliance, and respond to clients much faster.

Aviatrix customers saw significant benefits after deploying the company’s cloud network platform:

  • “Without Aviatrix, it would have taken an extra year and twice the staff” Sr. Infrastructure Architect, insurance company.
  • “We have been able to open new lines of business and keep up with increased demand” Assistant Director of Cloud Architecture and Engineering, manufacturer.
  • “We can shine a light in the dark corners of public cloud [with Aviatrix]” — Senior Cloud Architect, business software and services provider.
  • “With Aviatrix, we are saving millions” Assistant Director of Cloud Architecture and Engineering, manufacturer.

“We’re very pleased with the overall results of the Forrester TEI Study,” said Rod Stuhlmuller, Vice President of Product Marketing at Aviatrix. “The quantifiable data truly highlights the benefits our customers receive using the Aviatrix cloud network platform. Furthermore, our customers achieve these benefits in both single and multi-cloud environments. As more enterprises adopt a multi-cloud strategy, Aviatrix’s market leading solutions will be the foundation for demonstratable economic gains.”

Executive Summary Video of the TEI Study on Aviatrix: (5 mins)

Watch guest speaker Sean Owens, Forrester’s Principal Consultant, and leader of the TEI of Aviatrix cloud network platform study, provide an executive summary of the study’s methodology, key findings, and quantified results. View video here.

About Aviatrix

Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE ), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye